Dr. Ramya Rachamanti's Profile

M.B.B.S., M.D.(Pharmacology)

Dr. Ramya Rachamanti

Ramya hails from Guntur and has received Doctor of Medicine in Pharmacology from Guntur Medical College, Andhra Pradesh, India. She believes that the study of medicines is essential to the growth and completeness of a clinician to achieve higher levels of professionalism and service. Her hobbies are writing, listening to music and painting.

Written / Edited / Medically Reviewed

Ravulizumab

Ravulizumab generic Ravulizumab is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Cobimetinib

Cobimetinib generic Cobimetinib is a kinase inhibitor used in combination with another drug vemurafenib for treating patients with melanoma that cannot be operated or melanoma that spread to other parts of the body. Protein kinases are the enzymes which change the protein function by adding phosphate (PO4) group to the protein. Kinase inhibitor is an enzyme blocking this function.

Siltuximab

Siltuximab generic Siltuximab injection is used to treat patients suffering from multicentric Castlemanís disease (MCD) in which the disease involves multiple lymph nodes or other distant tissues of the body. Siltuximab must be prescribed only to patients who are having MCD, who are negative for Human Immunodeficiency Virus ( HIV ) and human herpesvirus-8 (HHV-8) negative.

Osimertinib

Osimertinib generic Osimertinib tablets are prescribed for non-small cell lung cancer that has spread to other parts of the body. Before using the drug ensure that the patients have specific gene mutations and this is confirmed by an FDA-approved test. Osimertinib is also recommended in patients whose cancer condition has progressed during or after other forms of treatments like EGFR tyrosine kinase inhibitor therapy.

Rolapitant

Rolapitant generic Rolapitant is prescribed to treat nausea and vomiting that occurs after several days in adult patients who undergo cancer chemotherapy. It is used in combination with other antiemetic agents in patients who are prescribed an initial or repeat course of cancer medications that can cause severe nausea and vomiting. Rolapitant works by blocking the action of certain substances (neurokinin and Substance P) in the brain and thereby reduces the stimulation for nausea and vomiting.